Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 11/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.42 |
| ▸ | MAPT | P10636 | 9/20 | 0.42 |
| ▸ | NPC1 | O15118 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28072963 | 0.79 | MAPT (0.52) | MEN1KMT2ARAB9AKDM4EMAPT | |
| SCHEMBL13049673 | 0.74 | ALDH1A1 (0.44) | MEN1KMT2ARAB9AKDM4EMAPT | |
| SCHEMBL13833847 | 0.74 | ADORA1 (0.51) | MEN1KMT2ANPSR1RAB9AKDM4E | |
| SCHEMBL8964766 | 0.70 | MAPT (0.56) | MEN1KMT2ANPSR1RAB9AKDM4E | |
| SCHEMBL28072961 | 0.70 | RAB9A (0.47) | MEN1KMT2ANPSR1RAB9AKDM4E | |
| SCHEMBL2962849 | 0.70 | KMT2A (0.53) | MEN1KMT2ANPSR1KDM4EMAPT | |
| SCHEMBL20017373 | 0.69 | MAPT (0.53) | MEN1KMT2ANPSR1RAB9AKDM4E | |
| SCHEMBL6510910 | 0.69 | PIK3CD (0.53) | MEN1KMT2ANPSR1RAB9AKDM4E | |
| SCHEMBL900512 | 0.69 | KDM4E (0.58) | MEN1KMT2ANPSR1RAB9AKDM4E | |
| SCHEMBL13049727 | 0.69 | CDC14B (0.41) | MEN1KMT2ANPSR1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7837981-B2 | Methods for imaging soluble A-beta | GENERAL ELECTRIC COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| EP-1631561-B1 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID | GEN ELECTRIC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7727511-B2 | Agents for imaging soluble a-beta | GENERAL ELECTRIC COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727511-B2 | Agents for imaging soluble a-beta | GENERAL ELECTRIC COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070189967-A1 | AGENTS FOR IMAGING SOLUBLE A-BETA | GENERAL ELECTRIC COMPANY (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070189967-A1 | AGENTS FOR IMAGING SOLUBLE A-BETA | GENERAL ELECTRIC COMPANY (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070140960-A1 | METHODS FOR IMAGING SOLUBLE A-BETA | GENERAL ELECTRIC COMPANY (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070140960-A1 | METHODS FOR IMAGING SOLUBLE A-BETA | APBA1, APP, FABP7 | MEN1 1513/4885KMT2A 4355/4885NPSR1 572/4885 |
| US-20070189967-A1 | AGENTS FOR IMAGING SOLUBLE A-BETA | APBA1, APP, FABP7 | MEN1 1254/4885KMT2A 4536/4885NPSR1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.